



Clinical Pharmacy Services and Their Impact on Patient Outcomes: Focus on Diabetes Mellitus

Post Congress Symposium

Held in Conjunction with The GCC Pharmaceutical Congress

Dubai, United Arab Emirates * September 17, 2014 * 9:00 a.m.–5:00 p.m.

TARGET AUDIENCE

Pharmacists and health care professionals and administrators

GOAL

Symposium goal is to provide an overview of the role and impact of clinical pharmacist services and review contemporary recommendations for the safe and effective management of type 2 diabetes mellitus.

LEARNING OBJECTIVES

1. Discuss patient-centered services provided by clinical pharmacists and outcomes of such services
2. Compare and contrast the currently marketed pharmacologic options for the management of type 2 diabetes mellitus
3. Outline strategies for the prevention and mitigation of adverse effects associated with the currently marketed pharmacologic agents
4. Summarize the most up-to-date recommendations for the optimal management of type 2 diabetes mellitus
5. Identify and assess the effectiveness of services and activities that advance clinical pharmacy practice and optimize patient outcomes

FACULTY



Adam J. Bursua, Pharm.D., BCPS

*Clinical Assistant Professor
College of Pharmacy
University of Illinois at Chicago*



Wafa Y. Dahdal, Pharm.D., BCPS

*Director of International Programs & Associate Director of
Professional Development
American College of Clinical Pharmacy*



Brian K. Irons, Pharm.D., FCCP, BCACP, BCPS, BC-ADM

*Associate Professor & Division Head for Ambulatory Care
School of Pharmacy
Texas Tech University Health Sciences Center*

FACULTY DISCLOSURES

Dr. Adam J. Bursua, Dr. Wafa Y. Dahdal, and Dr. Brian K. Irons have no relevant affiliations or financial relationships with a commercial interest to disclose.

AGENDA

9:00 a.m.

Welcome and Introduction

Wafa Y. Dahdal, Pharm.D., BCPS

1. Review the prevalence and burden of diabetes mellitus globally and in the Gulf region
2. Define clinical pharmacy

9:15 a.m.

Clinical Pharmacy Services and the Role of the Clinical Pharmacist

Wafa Y. Dahdal, Pharm.D., BCPS

1. Summarize advances in pharmacist provided services globally
2. Discuss the competencies for clinical pharmacists
3. Discuss the components of the process of care expected of clinical pharmacists
4. Recognize the evidence on economic evaluation of clinical pharmacy services

10:00 a.m.

Pharmacologic Management Armamentarium for Diabetes Mellitus: A Critical Review

Brian Irons, Pharm.D., FCCP, BCACP, BCPS, BC-ADM

1. Explain the main classes of medications used to treat diabetes mellitus in terms of mechanisms of action and sites of action in the human body
2. Describe the efficacy of each class of medication in diabetes management in their ability to improve glycemic control
3. List the monitoring parameters to consider for each class of agent in treating hyperglycemia
4. Explain the benefits and risks of each major class of medication used to treat diabetes mellitus

11:00 a.m.

Coffee Break

11:30 a.m.

Prevention and Mitigation of Adverse Outcomes Associated with Antidiabetes Agents

Adam J. Bursua, Pharm.D., BCPS

1. Recognize common and serious non-glycemic/idiosyncratic adverse reactions associated with various antidiabetic agents and drug classes

2. Compare and contrast the hypoglycemic risk of various antidiabetic drugs and treatment strategies
3. Identify characteristics that may predispose patients to adverse reactions associated with various antidiabetic agents
4. Describe strategies to mitigate risk of glycemic and idiosyncratic adverse reactions to antidiabetic therapy

12:30 p.m. **Prayer and Lunch**

1:30 p.m. **Evidence-Based Recommendations: Individualization of Therapy**

Brian Irons, Pharm.D., FCCP, BCACP, BCPS, BC-ADM

1. Compare and contrast the most recognized guidelines and consensus recommendations in the treatment of diabetes mellitus
2. Review the main determinants in selecting a particular agent to control hyperglycemia in a patient with diabetes
3. Describe how to determine individual treatment goals for a patient with diabetes

2:30 p.m. **Practice Management: Pharmacist Services and Impact on Patient Outcomes**

Adam J. Bursua, Pharm.D., BCPS

1. Describe successful pharmacy led initiatives that have improved outcomes of diabetes care
2. Recognize opportunities for pharmacists to improve diabetes care at the health-system level
3. Review the role of the pharmacist as a diabetes educator and coach

3:30 p.m. **Coffee Break**

4:00 p.m. **Patient Cases**

Symposium Faculty

1. Select an appropriate drug therapy recommendation for a patient-specific scenario based on a drug's efficacy and safety profile
2. Apply current evidence-based guidelines to a given patient-care scenario
3. Identify risk factors for adverse outcomes associated with anti-diabetic agents in an illustrative patient case
4. Recommend appropriate interventions to prevent and/or reduce adverse events associated with anti-diabetic medication in an illustrative patient case
5. Describe how both patient level and system level pharmacist interventions may improve patient care in an illustrative case

5:00 p.m. **Closing Remarks and Adjournment**

Wafa Y. Dahdal, Pharm.D., BCPS

CONTINUING PHARMACY EDUCATION CREDIT



The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE).

ACCP designates this CPE activity for 6.0 contact hours. Partial credit is not available for this activity.

Type of Activity: Knowledge-based
Universal Activity Number: 0217-0000-14-137-L01-P

To earn CPE credit for this activity, the participant must attend all 6.0 contact hours of programming, complete the associated evaluation, and claim credit at www.accp.com/ce by November 15, 2014.

To obtain a statement of credit for this activity, international participants must update their ACCP profile at www.accp.com/myaccount/licensure.aspx by checking the box "I am an international pharmacist, and do not have an NABP e-Profile ID". Participants with an NABP e-Profile ID on file with ACCP will obtain their statement of credit from www.cpemonitor.net.

CERTIFICATE OF ATTENDANCE

Certificates of attendance will be granted, at the conclusion of the activity, to participants taking part in the entire symposium.

REGISTRATION

Registration fees are as follows:

	Before May 27	Before July 17	Regular
Registration fee	\$299	\$349	\$399

Registration fee includes symposium booklet; opportunity to earn 6.0 CPE credit hours and a certificate of attendance issued to those meeting the criteria specified above; two coffee breaks and lunch.

To register for the symposium and reserve your seat, visit www.gccpharmacongress.com.

COMMERCIAL SUPPORT

No commercial support has been received for this activity.

